Omeros (OMER) Short term Debt (2011 - 2025)

Omeros (OMER) posted Short term Debt of $17.1 million for Q4 2025, down 36.64% sequentially from $26.9 million in Q1 2025.

Analysis

Omeros (OMER) Short term Debt (2011 - 2025) Analysis & Trends

Omeros has reported Short term Debt for 11 years, with the latest figure at $17.1 million in Q4 2025.

Quarterly Short term Debt changed N/A year-over-year to $17.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.1 million (changed N/A YoY) and the FY2025 annual result came in at $17.1 million, changed N/A from the prior year.
Short term Debt retreated to $17.1 million in Q4 2025 per OMER's latest filing, from $26.9 million in the prior quarter.
Over five years, Short term Debt peaked at $94.9 million in Q3 2023 and troughed at $17.1 million in Q4 2025.
A 3-year average of $70.4 million and a median of $94.5 million in 2022 frame the typical range for Short term Debt.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Omeros	1.38 Bn	1.38 Bn	27.73 Mn

Historic Data

Download Data